Knoll's atypical antipsychotic zotepine is set for more wide-spread use, now that the company has decided to pursue European Union-wide approval through the European Medicines Evaluation Agency.
A spokesman for the company told the Marketletter that zotepine was recently introduced in Austria, and has also been available in Germany since 1990. The drug was originated by Fujisawa of Japan, where it has been on the market since 1982. The spokesman said that the company had not yet made a decision on how it would approach the US market for zotepine.
Knoll believes that zotepine will be popular with physicians because of the long-term experience with the compound in Japan. Like other atypical antipsychotics, zotepine is associated with a low incidence of extrapyramidal side effects. In particular, the drug has not been associated with tardive dyskinesia.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze